GLP-1 agonism is an established pharmacological target for treating type 2 diabetes and obesity, however it is unclear whether pharmacological GIP agonism represents a similar therapeutic opportunity [2]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.